<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">phkinetica-25</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЯ ФАРМАКОКИНЕТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOKINETICS STUDIES</subject></subj-group></article-categories><title-group><article-title>Влияние трифтазина на проявления расстройств аутистического спектра у крыс с фетальным вальпроатным синдромом</article-title><trans-title-group xml:lang="en"><trans-title>Effect of triftazin (trifluoperazine) on the symptoms of autism spectrum disorders in rats with fetal valproatate syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Капица</surname><given-names>Инга Геннадиевна</given-names></name><name name-style="western" xml:lang="en"><surname>Kapitsa</surname><given-names>I. G.</given-names></name></name-alternatives><email xlink:type="simple">ingakap73@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanova</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронина</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Voronina</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Процун</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Protsun</surname><given-names>G. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГБНУ «НИИ фармакологии имени В.В. Закусова»</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>08</day><month>07</month><year>2017</year></pub-date><volume>0</volume><issue>3</issue><fpage>34</fpage><lpage>38</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Капица И.Г., Иванова Е.А., Воронина Т.А., Процун Г.В., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Капица И.Г., Иванова Е.А., Воронина Т.А., Процун Г.В.</copyright-holder><copyright-holder xml:lang="en">Kapitsa I.G., Ivanova E.A., Voronina T.A., Protsun G.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/25">https://www.pharmacokinetica.ru/jour/article/view/25</self-uri><abstract><p>На модели фетального вальпроатного синдрома у крыс изучено влияние трифтазина на нарушение социального взаимодействия как основного показателя расстройства аутистического спектра, а также на ориентировочно-исследовательское поведение и способность к обучению животных. Показано, что трифтазин в дозе 0,35 мг/кг не влияет на дефицит социального взаимодействия и показатели пространственного обучения и памяти, но улучшает ориентировочно-исследовательскую активность за счёт снижения тревожности у крыс с фетальным вальпроатным синдромом.</p></abstract><trans-abstract xml:lang="en"><p>The effect of triftazin (trifluoperazine) on social interaction abnormalities as a main feature of autism spectrum disorders, exploratory behavior and learning capacity was studied in rats with fetal valproatate syndrome. It was shown that triftazin at a dose of 0,35 mg/kg does not affect the deficit of social interaction, spatial learning or memory but improves exploratory activity by decreasing anxiety in rats with fetal valproate syndrome.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>трифтазин</kwd><kwd>вальпроевая кислота</kwd><kwd>фетальный вальпроатный синдром</kwd><kwd>расстройства аутистического спектра</kwd><kwd>социальное взаимодействие</kwd><kwd>тревожность</kwd><kwd>triftazin</kwd><kwd>valproic acid</kwd><kwd>fetal valproate syndrome</kwd><kwd>autism spectrum disorders</kwd><kwd>social interaction</kwd><kwd>anxiety</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">IACAPAP Textbook of Child and Adolescent Mental Health. Autism spectrumdisorder 2015; 2: 1-38.</mixed-citation><mixed-citation xml:lang="en">IACAPAP Textbook of Child and Adolescent Mental Health. Autism spectrumdisorder 2015; 2: 1-38.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wallace S., Fein D., Rosanoff M., et al. A global public health strategy for autism spectrum disorders. Autism Res. 2012; 5 (3): 211-217.</mixed-citation><mixed-citation xml:lang="en">Wallace S., Fein D., Rosanoff M., et al. A global public health strategy for autism spectrum disorders. Autism Res. 2012; 5 (3): 211-217.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Психиатрия детского и подросткового возраста под ред. Гилл-берга К., Хеллгрена Л., рус. изд. / под общ. ред. акад. РАМН Сидорова П.И. М.: ГЭОТАР-МЕД, 2004; 544.</mixed-citation><mixed-citation xml:lang="en">Психиатрия детского и подросткового возраста под ред. Гилл-берга К., Хеллгрена Л., рус. изд. / под общ. ред. акад. РАМН Сидорова П.И. М.: ГЭОТАР-МЕД, 2004; 544.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Симашкова Н.В. Эффективная фармакотерапия и реабилитация больных с расстройствами аутистического спектра. Неврология и психиатрия 2011; 3: 14-22.</mixed-citation><mixed-citation xml:lang="en">Симашкова Н.В. Эффективная фармакотерапия и реабилитация больных с расстройствами аутистического спектра. Неврология и психиатрия 2011; 3: 14-22.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Шапошникова А.Ф. Медикаментозное лечение при детском аутизме. Аутизм и нарушение развития. 2008; 3: 43 -48.</mixed-citation><mixed-citation xml:lang="en">Шапошникова А.Ф. Медикаментозное лечение при детском аутизме. Аутизм и нарушение развития. 2008; 3: 43 -48.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Doyle C.A., McDougle C.J. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012; 14: 263-279.</mixed-citation><mixed-citation xml:lang="en">Doyle C.A., McDougle C.J. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012; 14: 263-279.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Венгеровский А.И. Лекции по фармакологии для врачей и провизоров. М.: Физматлит. 2007; 3-е изд. 199 -210.</mixed-citation><mixed-citation xml:lang="en">Венгеровский А.И. Лекции по фармакологии для врачей и провизоров. М.: Физматлит. 2007; 3-е изд. 199 -210.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chomiak T., Turner N., Hu B. What we have learned about autism spectrum disorder from valproic acid. Pathology Research International 2013; 2013: 712-758.</mixed-citation><mixed-citation xml:lang="en">Chomiak T., Turner N., Hu B. What we have learned about autism spectrum disorder from valproic acid. Pathology Research International 2013; 2013: 712-758.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kerr D.M., Downey L., Conboy M., et al. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behavioural Brain Research 2013; 249: 124-132.</mixed-citation><mixed-citation xml:lang="en">Kerr D.M., Downey L., Conboy M., et al. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behavioural Brain Research 2013; 249: 124-132.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gottfried C., Bambini-Junior V., Baronio D., et al. Valproic Acid in Autism Spectrum Disorder: From an Environmental Risk Factor to a Reliable Animal Model. In: Recent Advances in Autism Spectrum Disorders. InTech, Chapters published. 2013; 1. Ch.8.: 143-163.</mixed-citation><mixed-citation xml:lang="en">Gottfried C., Bambini-Junior V., Baronio D., et al. Valproic Acid in Autism Spectrum Disorder: From an Environmental Risk Factor to a Reliable Animal Model. In: Recent Advances in Autism Spectrum Disorders. InTech, Chapters published. 2013; 1. Ch.8.: 143-163.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Silverman J.L., Yang M., Lord K., Crawley J.N. Behavioral phenotyping assay for mouse models of autism. Nat Rev Neurosci. 2010; 11 (7): 490 -502.</mixed-citation><mixed-citation xml:lang="en">Silverman J.L., Yang M., Lord K., Crawley J.N. Behavioral phenotyping assay for mouse models of autism. Nat Rev Neurosci. 2010; 11 (7): 490 -502.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Foley A.G., Gannon S., Rombach-mullan N., et al. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder. Neuropharmacology 2012;63(4): 750-760.</mixed-citation><mixed-citation xml:lang="en">Foley A.G., Gannon S., Rombach-mullan N., et al. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder. Neuropharmacology 2012;63(4): 750-760.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ingram J.L., Peckham S.M., Tisdale B., Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicology and Teratology 2000; 22: 319-324.</mixed-citation><mixed-citation xml:lang="en">Ingram J.L., Peckham S.M., Tisdale B., Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicology and Teratology 2000; 22: 319-324.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Mental Retardation and Developmental Disabilities Research Reviews 2004; 10: 248-58.</mixed-citation><mixed-citation xml:lang="en">Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Mental Retardation and Developmental Disabilities Research Reviews 2004; 10: 248-58.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kaidanovich-Beilin O., Lipina T., Vukobradovic I., Roder J., Woodgett J.R. Assessment of Social Interaction Behaviors. J. Vis. Exp. 2011; 48: 2473.</mixed-citation><mixed-citation xml:lang="en">Kaidanovich-Beilin O., Lipina T., Vukobradovic I., Roder J., Woodgett J.R. Assessment of Social Interaction Behaviors. J. Vis. Exp. 2011; 48: 2473.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Островская Р.У., Раевский К.С., Воронина Т.А. и др. в «Руководстве по проведению доклинических исследований лекарственных средств» Часть 1, Москва, изд-во «Гриф и К» ФГБУ «НЦЭМСП» Минздравсоцразвития России, 2012; 251-263.</mixed-citation><mixed-citation xml:lang="en">Островская Р.У., Раевский К.С., Воронина Т.А. и др. в «Руководстве по проведению доклинических исследований лекарственных средств» Часть 1, Москва, изд-во «Гриф и К» ФГБУ «НЦЭМСП» Минздравсоцразвития России, 2012; 251-263.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Калинина Т.С., Шимширт А.А., Кудряшов Н.В. и др. Нейростеро-идогенез и ориентировочно-исследовательское поведение грызунов. Экспер. и клин. фармак. 2014; 77 (2): 3-7.</mixed-citation><mixed-citation xml:lang="en">Калинина Т.С., Шимширт А.А., Кудряшов Н.В. и др. Нейростеро-идогенез и ориентировочно-исследовательское поведение грызунов. Экспер. и клин. фармак. 2014; 77 (2): 3-7.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Adelaiye A, Agunu A. Effect of Ziziphus mauritiania (L.) seed extracts on spatial recognition memory of rats as measured by the Y-maze test. Journal of Natural Products. 2009; 2: 31-39.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Adelaiye A, Agunu A. Effect of Ziziphus mauritiania (L.) seed extracts on spatial recognition memory of rats as measured by the Y-maze test. Journal of Natural Products. 2009; 2: 31-39.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Iwata K., Izumo N., Matsuzaki H., et al. Vldlr overexpression causes hyperactivity in rats. Molecular Autism 2012; 3: 11.</mixed-citation><mixed-citation xml:lang="en">Iwata K., Izumo N., Matsuzaki H., et al. Vldlr overexpression causes hyperactivity in rats. Molecular Autism 2012; 3: 11.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
